{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:02:26Z","timestamp":1790946146071,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41375-023-02062-0","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T13:03:12Z","timestamp":1697547792000},"page":"2426-2435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0694-1496","authenticated-orcid":false,"given":"Andrew","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8586-6092","authenticated-orcid":false,"given":"Ryan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8721-5295","authenticated-orcid":false,"given":"Sarah","family":"Grasedieck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-1926","authenticated-orcid":false,"given":"Connie J.","family":"Eaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7340","authenticated-orcid":false,"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2062_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"2062_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR::ABL1 positive cells. Nat Med. 1996;2:561\u20136.","journal-title":"Nat Med"},{"key":"2062_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2006","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2006;109:58\u201360.","journal-title":"Blood."},{"key":"2062_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood."},{"key":"2062_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","volume":"11","author":"V Nardi","year":"2004","unstructured":"Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11:35\u201343.","journal-title":"Curr Opin Hematol"},{"key":"2062_CR6","doi-asserted-by":"crossref","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8. https:\/\/pubmed.ncbi.nlm.nih.gov\/17976612\/.","DOI":"10.1016\/S1470-2045(07)70342-X"},{"key":"2062_CR7","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"A Hochhaus","year":"2002","unstructured":"Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190\u20136.","journal-title":"Leukemia."},{"key":"2062_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR::ABL1. Cancer Cell. 2005;7:129\u201341.","journal-title":"Cancer Cell"},{"key":"2062_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399\u2013401.","journal-title":"Science."},{"key":"2062_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00823-9","volume":"13","author":"J Senapati","year":"2023","unstructured":"Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J. 2023;13:58.","journal-title":"Blood Cancer J."},{"key":"2062_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917.","journal-title":"N Engl J Med"},{"key":"2062_CR12","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia."},{"key":"2062_CR13","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1002\/cam4.1753","volume":"7","author":"HY Song","year":"2018","unstructured":"Song HY, Noh H, Choi SY, Lee SE, Kim SH, Kee KM, et al. BCR::ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors. Cancer Med. 2018;7:5107\u201317.","journal-title":"Cancer Med"},{"key":"2062_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","volume":"5","author":"RE Clark","year":"2021","unstructured":"Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5:1102\u20139.","journal-title":"Blood Adv"},{"key":"2062_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29923-4","volume":"8","author":"I Glauche","year":"2018","unstructured":"Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, et al. Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison. Sci Rep. 2018;8:12330.","journal-title":"Sci Rep"},{"key":"2062_CR16","doi-asserted-by":"crossref","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9. https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2018.00402.","DOI":"10.3389\/fendo.2018.00402"},{"key":"2062_CR17","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","volume":"1","author":"Y Peng","year":"2016","unstructured":"Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.","journal-title":"Signal Transduct Target Ther"},{"key":"2062_CR18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","volume":"20","author":"J Hayes","year":"2014","unstructured":"Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460\u20139.","journal-title":"Trends Mol Med"},{"key":"2062_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46132-9","volume":"9","author":"R Alves","year":"2019","unstructured":"Alves R, Gon\u00e7alves AC, Jorge J, Marques G, Lu\u00eds D, Ribeiro AB, et al. MicroRNA signature refine response prediction in CML. Sci Rep. 2019;9:9666.","journal-title":"Sci Rep"},{"key":"2062_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ddr.21266","volume":"76","author":"K Kotagama","year":"2015","unstructured":"Kotagama K, Chang Y, Mangone M. miRNAs as biomarkers in chronic myelogenous leukemia. Drug Dev Res. 2015;76:278\u201385.","journal-title":"Drug Dev Res"},{"key":"2062_CR21","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fonc.2020.01544","volume":"10","author":"JRB Martins","year":"2020","unstructured":"Martins JRB, de Moraes LN, Cury SS, Dadalto J, Capannacci J, Carvalho RF, et al. Comparison of microRNA expression profile in chronic myeloid leukemia patients newly diagnosed and treated by allogeneic hematopoietic stem cell transplantation. Front Oncol. 2020;10:1544.","journal-title":"Front Oncol"},{"key":"2062_CR22","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","volume":"76","author":"AA Svoronos","year":"2016","unstructured":"Svoronos AA, Engelman DM, Slack FJ. OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res. 2016;76:3666\u201370.","journal-title":"Cancer Res"},{"key":"2062_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-41","volume":"10","author":"K Machov\u00e1 Pol\u00e1kov\u00e1","year":"2011","unstructured":"Machov\u00e1 Pol\u00e1kov\u00e1 K, Lopotov\u00e1 T, Klamov\u00e1 H, Burda P, Trn\u011bn\u00fd M, Stopka T, et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer. 2011;10:41.","journal-title":"Mol Cancer"},{"key":"2062_CR24","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41375-022-01680-4","volume":"36","author":"R Yen","year":"2022","unstructured":"Yen R, Grasedieck S, Wu A, Lin H, Su J, Rothe K, et al. Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial. Leukemia. 2022;36:2443\u201352.","journal-title":"Leukemia."},{"key":"2062_CR25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1182\/blood-2009-05-222471","volume":"116","author":"X Jiang","year":"2010","unstructured":"Jiang X, Forrest D, Nicolini F, Turhan A, Guilhot J, Yip C, et al. Properties of CD34+ CML stem\/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood. 2010;116:2112\u201321.","journal-title":"Blood."},{"key":"2062_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1182\/blood.2019003636","volume":"136","author":"H Lin","year":"2020","unstructured":"Lin H, Rothe K, Chen M, Wu A, Babaian A, Yen R, et al. The miR-185\/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML. Blood. 2020;136:596\u2013609.","journal-title":"Blood."},{"key":"2062_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121\u201337.","journal-title":"Comput Stat Data Anal"},{"key":"2062_CR28","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014 from molecular mechanisms to clinical relevance. Cancers. 2021;13:4820.","journal-title":"Cancers"},{"key":"2062_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW. Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin N Am. 2017;31:589\u2013612.","journal-title":"Hematol Oncol Clin N Am"},{"key":"2062_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","volume":"9","author":"F Loscocco","year":"2019","unstructured":"Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR::ABL1 Independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939.","journal-title":"Front Oncol"},{"key":"2062_CR31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"M Houshmand","year":"2019","unstructured":"Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, et al. Chronic myeloid leukemia stem cells. Leukemia. 2019;33:1543\u201356.","journal-title":"Leukemia."},{"key":"2062_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR::ABL1 activity. J Clin Investig. 2011;121:396\u2013409.","journal-title":"J Clin Investig"},{"key":"2062_CR33","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jnci\/djk150","volume":"99","author":"X Jiang","year":"2007","unstructured":"Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR::ABL1 gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst. 2007;99:680\u201393.","journal-title":"J Natl Cancer Inst"},{"key":"2062_CR34","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/sj.leu.2404609","volume":"21","author":"X Jiang","year":"2007","unstructured":"Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007;21:926\u201335.","journal-title":"Leukemia."},{"key":"2062_CR35","doi-asserted-by":"publisher","first-page":"e2486","DOI":"10.1097\/MD.0000000000002486","volume":"95","author":"YZ Qin","year":"2016","unstructured":"Qin YZ, Jiang Q, Jiang H, Lai YY, Zhu HH, Liu YR, et al. Combination of white blood cell count at presentation with molecular response at 3 months better predicts deep molecular responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Medicine. 2016;95:e2486.","journal-title":"Medicine"},{"key":"2062_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3332\/ecancer.2016.679","volume":"10","author":"LC Kuntegowdanahalli","year":"2016","unstructured":"Kuntegowdanahalli LC, Kanakasetty GB, Thanky AH, Dasappa L, Jacob LA, Mallekavu SB, et al. Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era-experience from a tertiary oncology centre in Southern India. Ecancermedicalscience. 2016;10:679.","journal-title":"Ecancermedicalscience."},{"key":"2062_CR37","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41375-021-01387-y","volume":"36","author":"XS Zhang","year":"2022","unstructured":"Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022;36:482\u201391.","journal-title":"Leukemia."},{"key":"2062_CR38","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, et al. Combining BCR::ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013;121:2739\u201342.","journal-title":"Blood."},{"key":"2062_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR::ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232\u20138.","journal-title":"J Clin Oncol"},{"key":"2062_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CHM Jamieson","year":"2004","unstructured":"Jamieson CHM, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657\u201367.","journal-title":"N Engl J Med"},{"key":"2062_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31557\/APJCP.2021.22.1.111","volume":"22","author":"M Bagheri","year":"2021","unstructured":"Bagheri M, Khansarinejad B, Mosayebi G, Moradabadi A, Mondanizadeh M. Diagnostic value of plasma miR-145 and miR-185 as targeting of the APRIL oncogene in the B-cell chronic lymphocytic leukemia. Asian Pac J Cancer Prev. 2021;22:111\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2062_CR42","doi-asserted-by":"publisher","first-page":"104296","DOI":"10.1016\/j.mvr.2021.104296","volume":"140","author":"B Pang","year":"2022","unstructured":"Pang B, Mao H, Wang J, Yang W. MiR-185-5p suppresses acute myeloid leukemia by inhibiting GPX1. Microvasc Res. 2022;140:104296.","journal-title":"Microvasc Res"},{"key":"2062_CR43","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/cas.14517","volume":"111","author":"W Xu","year":"2020","unstructured":"Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, et al. MiR-145 in cancer therapy resistance and sensitivity: a comprehensive review. Cancer Sci. 2020;111:3122\u201331.","journal-title":"Cancer Sci"},{"key":"2062_CR44","first-page":"6739","volume":"11","author":"WX Xu","year":"2019","unstructured":"Xu WX, Liu Z, Deng F, Wang DD, Li XW, Tian T, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11:6739\u201353.","journal-title":"Am J Transl Res"},{"key":"2062_CR45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/CMAR.S191696","volume":"11","author":"D Ye","year":"2019","unstructured":"Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res. 2019;11:969\u201379.","journal-title":"Cancer Manag Res"},{"key":"2062_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-019-0933-8","volume":"19","author":"S Manvati","year":"2019","unstructured":"Manvati S, Mangalhara KC, Kalaiarasan P, Chopra R, Agarwal G, Kumar R, et al. miR-145 supports cancer cell survival and shows association with DDR genes, methylation pattern, and epithelial to mesenchymal transition. Cancer Cell Int. 2019;19:230.","journal-title":"Cancer Cell Int"},{"key":"2062_CR47","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.humpath.2014.01.017","volume":"45","author":"H Xia","year":"2014","unstructured":"Xia H, Yamada S, Aoyama M, Sato F, Masaki A, Ge Y, et al. Prognostic impact of microRNA-145 down-regulation in adult T-cell leukemia\/lymphoma. Hum Pathol. 2014;45:1192\u20138.","journal-title":"Hum Pathol"},{"key":"2062_CR48","first-page":"1289","volume":"46","author":"Z Wuxiao","year":"2020","unstructured":"Wuxiao Z, Wang H, Su Q, Zhou H, Hu M, Tao S, et al. MicroRNA-145 promotes the apoptosis of leukemic stem cells and enhances drug-resistant K562\/ADM cell sensitivity to adriamycin via the regulation of ABCE1. Int J Mol Med. 2020;46:1289\u2013300.","journal-title":"Int J Mol Med"},{"key":"2062_CR49","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.leukres.2011.09.027","volume":"36","author":"AJ Favreau","year":"2012","unstructured":"Favreau AJ, Sathyanarayana P. miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia. Leuk Res. 2012;36:334\u201341.","journal-title":"Leuk Res"},{"key":"2062_CR50","doi-asserted-by":"publisher","first-page":"101042831988134","DOI":"10.1177\/1010428319881344","volume":"41","author":"L Rios-Colon","year":"2019","unstructured":"Rios-Colon L, Deep G, Kumar D. Emerging role of microRNA 628-5p as a novel biomarker for cancer and other diseases. Tumour Biol. 2019;41:1010428319881344.","journal-title":"Tumour Biol"},{"key":"2062_CR51","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/oncsis.2017.66","volume":"6","author":"I Daugaard","year":"2017","unstructured":"Daugaard I, Sanders KJ, Idica A, Vittayarukskul K, Hamdorf M, Krog JD, et al. miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis. 2017;6:e366.","journal-title":"Oncogenesis."},{"key":"2062_CR52","doi-asserted-by":"publisher","first-page":"6180","DOI":"10.1038\/s41388-021-02011-0","volume":"40","author":"B Li","year":"2021","unstructured":"Li B, Xia Y, Lv J, Wang W, Xuan Z, Chen C, et al. miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche. Oncogene. 2021;40:6180\u201394.","journal-title":"Oncogene."},{"key":"2062_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/or.2023.8487","volume":"49","author":"Y Xie","year":"2023","unstructured":"Xie Y, Zhang Y, Liu X, Cao L, Han M, Wang C, et al. miR-151a-5p ppromotes the proliferation and metastasis of colorectal carcinoma cells by targeting AGMAT. Oncol Rep. 2023;49:50.","journal-title":"Oncol Rep"},{"key":"2062_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hon.2567","volume":"37","author":"RS Almeida","year":"2019","unstructured":"Almeida RS, Costa e Silva M, Coutinho LL, Garcia Gomes R, Pedrosa F, Massaro JD, et al. MicroRNA expression profiles discriminate childhood T- from B-acute lymphoblastic leukemia. Hematol. Oncol. 2019;37:103\u201312.","journal-title":"Hematol. Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02062-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02062-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02062-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T09:04:28Z","timestamp":1701075868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02062-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02062-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Research funding: Bristol-Myers Squibb Canada (DLF, CE and XJ). Other authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}